论文部分内容阅读
本文采用多聚酶链反应(PCR)的方法检测了21例非何杰金淋巴瘤病人的瘤组织16份,骨髓26份和外周血25份中的癌基因bcl—2mRNA,并对bcl—2的阳性表达与病人的临床特征进行了相关性研究。结果:疗前9例细胞淋巴瘤的5份肿瘤组织、骨髓和外周血各9份中bcl—2均阴性。疗前11例B细胞淋巴瘤的肿瘤组织中7例阳性(63.6％),其中5例滤泡型4例阳性(80％);6例弥漫型3例阳性(50％);12例骨髓中5例阳性(41.7％),滤泡型和弥漫型的阳性率分别为40％(2/5)和42.9％(3/7),疗前12例外周血4例bcl—2阳性(33.3％),滤泡型和弥漫型的阳性率分别为20％(1/5)和42.9(3/7);对疗前阳性骨髓5例和外周血4例化疗后复查骨髓和外周血各有2例阴转,其余仍呈阴性表达。通过与临床特征的相关比较表明肿瘤组织中bcl—2mRNA阳性表达与临床分Ⅰ期及疗效间无明显相关性(P>0.05),骨髓和外周血的阳性率与临床分期偏晚有关(P<0.05)。结论:结合文献,本文提示,癌基因bcl—2可作为B细胞淋巴瘤的分子标记物,尤其是滤泡型,对早期诊断有意义,通过对B细胞淋巴瘤的骨髓及外周血的bcl—2检测,可能对分期和疗效监测有重要意义。
In this paper, 16 cases of non-Hodgkin’s lymphoma in 21 cases, 26 cases of bone marrow and 25 cases of peripheral blood were detected by polymerase chain reaction (PCR), and the bcl-2 mRNA was positive for bcl-2. The correlation between the expression and the patient’s clinical characteristics was studied. RESULTS: Bcl-2 was negative in 9 tumor tissues, bone marrow, and peripheral blood of 9 cases of cell lymphoma before treatment. Among the 11 cases of B-cell lymphoma before treatment, 7 cases were positive (63.6%), of which 5 cases were positive (80%) in follicular type, 6 cases were diffuse in 3 cases (50%), and 12 cases were in bone marrow. Five cases were positive (41.7%), follicular type and diffuse type positive rates were 40% (2/5) and 42.9% (3/7), respectively, and before therapy, 4 cases of peripheral blood were bcl-2 positive (33.3%). The positive rates of follicular and diffuse types were 20% (1/5) and 42.9 (3/7), respectively; 5 cases of positive bone marrow before treatment and 4 cases of peripheral blood were examined after chemotherapy for bone marrow and peripheral blood. Cases of negative conversion, the remaining still negative expression. The correlation with clinical features showed that the positive expression of bcl-2 mRNA in tumor tissues was not significantly related to clinical stage I and efficacy (P>0.05). The positive rate of bone marrow and peripheral blood was related to late clinical stage (P< 0.05). Conclusion: Combined with the literature, this article suggests that the oncogene bcl-2 can be used as a molecular marker of B-cell lymphomas, especially follicular type, and is of significance for early diagnosis, through the bone marrow and peripheral blood bcl of B-cell lymphoma. 2 Testing may have important implications for staging and efficacy monitoring.